Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More?
作者信息
Roh Ji Woong, Kim Yongcheol
机构信息
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin, Korea.
出版信息
Korean Circ J. 2022 Jul;52(7):556-557. doi: 10.4070/kcj.2022.0105. Epub 2022 May 16.
Abstract
摘要
相似文献
1
Role of β-Blockers in Chronic Coronary Artery Disease Management in the Percutaneous Coronary Intervention Era: Good Symptom Control or Something More?β受体阻滞剂在经皮冠状动脉介入治疗时代慢性冠状动脉疾病管理中的作用：良好的症状控制还是另有其他？
Korean Circ J. 2022 Jul;52(7):556-557. doi: 10.4070/kcj.2022.0105. Epub 2022 May 16.
2
Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results.β受体阻滞剂治疗经皮血运重建术治疗的冠心病患者降低死亡率：调整结果的荟萃分析。
J Cardiovasc Med (Hagerstown). 2018 Jul;19(7):337-343. doi: 10.2459/JCM.0000000000000662.
3
Long-term impact of β-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention.β受体阻滞剂对行经皮冠状动脉介入治疗的老年非心肌梗死患者的长期影响。
ESC Heart Fail. 2022 Feb;9(1):545-554. doi: 10.1002/ehf2.13715. Epub 2021 Nov 22.
4
Beta blockers versus calcium channel blockers for provocation of vasospastic angina after drug-eluting stent implantation: a multicentre prospective randomised trial.药物洗脱支架植入术后β受体阻滞剂与钙通道阻滞剂诱发血管痉挛性心绞痛的比较：一项多中心前瞻性随机试验。
Open Heart. 2020 Oct;7(2). doi: 10.1136/openhrt-2020-001406.
5
The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention.β受体阻滞剂治疗对经皮冠状动脉介入治疗后慢性冠状动脉疾病患者的临床影响。
Korean Circ J. 2022 Jul;52(7):544-555. doi: 10.4070/kcj.2021.0395. Epub 2022 Apr 4.
6
Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials.ST段抬高型心肌梗死患者接受直接经皮冠状动脉介入治疗时早期静脉注射β受体阻滞剂：一项随机临床试验的患者汇总荟萃分析。
Eur Heart J Acute Cardiovasc Care. 2020 Aug;9(5):469-477. doi: 10.1177/2048872619830609. Epub 2019 Feb 14.
7
Beta-blockers in the management of coronary artery disease: are we on the verge of a new paradigm shift?β受体阻滞剂在冠状动脉疾病管理中的应用：我们是否正处在新范式转变的边缘？
Recent Pat Cardiovasc Drug Discov. 2014;9(1):11-21. doi: 10.2174/1574890109666140901144210.
8
Prognostic impacts of β-blockers in acute coronary syndrome patients without heart failure treated by percutaneous coronary intervention.β 受体阻滞剂对行经皮冠状动脉介入治疗的无心力衰竭急性冠状动脉综合征患者的预后影响。
Pharmacol Res. 2021 Jul;169:105614. doi: 10.1016/j.phrs.2021.105614. Epub 2021 Apr 16.
9
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.慢性稳定型心绞痛治疗的最新进展II. 抗缺血治疗、难治性心绞痛的治疗选择、危险因素的降低及血运重建
Vasc Health Risk Manag. 2010 Sep 7;6:749-74. doi: 10.2147/vhrm.s11100.
10
Chronic Kidney Disease and Post-Percutaneous Coronary Intervention Mortality in Patients With Left Main and Equivalent Coronary Artery Disease.慢性肾脏病与左主干及等效冠状动脉疾病患者经皮冠状动脉介入治疗后死亡率。
Tex Heart Inst J. 2022 Sep 1;49(5). doi: 10.14503/THIJ-21-7670.
本文引用的文献
1
The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention.β受体阻滞剂治疗对经皮冠状动脉介入治疗后慢性冠状动脉疾病患者的临床影响。
Korean Circ J. 2022 Jul;52(7):544-555. doi: 10.4070/kcj.2021.0395. Epub 2022 Apr 4.
2
Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.射血分数降低的心力衰竭患者的药物治疗
Korean Circ J. 2022 Mar;52(3):173-197. doi: 10.4070/kcj.2021.0401.
3
Clinical Impact of Beta Blockers in Patients with Myocardial Infarction from the Korean National Health Insurance Database.来自韩国国民健康保险数据库的β受体阻滞剂对心肌梗死患者的临床影响
Korean Circ J. 2020 Jun;50(6):499-508. doi: 10.4070/kcj.2019.0231. Epub 2020 Jan 6.
4
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.2019年欧洲心脏病学会慢性冠状动脉综合征诊断和管理指南
Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425.
5
'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization.2018年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南的“十诫”
Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855.
6
Expert consensus document: A 'diamond' approach to personalized treatment of angina.专家共识文件：一种针对心绞痛的个体化治疗的“钻石”方法。
Nat Rev Cardiol. 2018 Feb;15(2):120-132. doi: 10.1038/nrcardio.2017.131. Epub 2017 Sep 7.
7
β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.β受体阻滞剂与无心力衰竭心肌梗死患者的死亡率：多中心前瞻性队列研究
BMJ. 2016 Sep 20;354:i4801. doi: 10.1136/bmj.i4801.
8
Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.与接受择期经皮冠状动脉介入治疗的稳定型心绞痛患者中使用β受体阻滞剂相关的预测因素、趋势和结局（年龄≥65 岁的老年患者）：来自 NCDR 注册研究的结果。
JACC Cardiovasc Interv. 2016 Aug 22;9(16):1639-48. doi: 10.1016/j.jcin.2016.05.048.
9
β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.β受体阻滞剂在经皮冠状动脉介入治疗后的患者中的应用：一概而论？无心肌梗死或心力衰竭的患者结局更差。
Int J Cardiol. 2013 Sep 30;168(2):774-9. doi: 10.1016/j.ijcard.2012.10.001. Epub 2012 Nov 2.
10
Effect of carvedilol on survival in severe chronic heart failure.卡维地洛对严重慢性心力衰竭患者生存率的影响。
N Engl J Med. 2001 May 31;344(22):1651-8. doi: 10.1056/NEJM200105313442201.
Zotero 插件